Cousin Surgery Acquires PlantTec Medical

Lüneburg, Germany and Wervicq-Sud, France – April 27th, 2023

Cousin Surgery, a leading implantable medical device company, has successfully completed
the acquisition of PlantTec Medical, a prominent German surgical medical device firm
specializing in hemostatic and adhesion prevention solutions.
PlantTec Medical is the first company in the world to CE-certify a plant-based product for
surgery that not only effectively stops surgical bleeding, but also substantially prevents
postoperative tissue adhesions. The polysaccharide-based product 4DRYFIELD® has been
used more than 350,000 times in surgical procedures. Their innovative solutions are currently
sold in over 30 countries in hospitals and clinics worldwide through distributors and through
an established direct salesforce in Germany.
Cousin Surgery is a French group specialized in implantable medical devices with a
longstanding industrial expertise. Today, the company is a recognized as a specialist in
implantable textiles and their application to spine and visceral surgery.
Private equity healthcare specialist fund of Turenne Group, Capital Santé 2, with his co-
investors – Nord Capital Investissement, Sélection & Opportunités (Turenne Group), Dalle &
Associés and Altur Investissement – and the Management have funded Cousin Surgery in its
acquisition of PlantTec Medical.
The acquisition of PlantTec Medical will create immediate cross-selling opportunities and
drive R&D innovation for Cousin Surgery. « PlantTec Medical provides us with an exceptional
team possessing deep expertise in delivering surgical medical device solutions for patients
especially in Germany. » say Cousin Surgery’s CEOs, François Tortel and François Henin. « This
acquisition significantly expands our high-quality portfolio, addressing the needs of
physicians and patients in vascular, gynecological, orthopedic, and general surgery. It’s a
perfect fit for us. »
In a strategic move, PlantTec Medical’s founders and CEOs, Ellen and Joachim Laas, will not
only remain in the company but also invest in the group. « This deal propels 4DRYFIELD® and
PlantTec Medical to the next level of global growth, » they state.
Raquel Pires and Benoît Pastour, Executive Director and Managing Director at Turenne
Capital, expressed their pride in the strategic transaction with PlantTec Medical. « We’ve
closely monitored the company’s growth over the past years and recognize its full potential,
driven by a talented management team that we are thrilled to work with now. »
Edouard Nuttin, CEO, and Jean-Bastien Bloch, Investment Manager at Roquette Ventures,
commented: « We’re proud to have supported PlantTec Medical and its management team in
their remarkable growth since its inception. This journey, aligned with Roquette Venture’s
approach, has resulted in significant geographical expansion and impressive commercial
traction. We’re pleased to see PlantTec Medical join an ambitious new project and are

excited about the opportunities and synergies with Cousin Surgery. We wish Ellen, Joachim
Laas, and their team all the success they deserve in this new venture. »
Dr. Edouard Gobitz, Managing Partner Asklepios Advisors, Healthcare Investment Bank
added: “Our firm is proud to have supported Roquette Ventures & PlantTec Medical
founders. This transaction demonstrates Asklepios Advisors commitment to supporting
healthcare clients over the long term in all stages of their development.”
Asklepios Advisors served as Roquette Group and PlantTec Medical’s exclusive financial
advisor, with Osborne Clarke as the legal advisor for the seller.
Kroll (finance, tax due diligence), McDermott Will Emery (legal, social due diligence) and
Lamartine Conseil (legal advisor for financing) supported the buyer. The existing pool of
banks, Crédit Agricole Mutuel Nord de France, CIC Nord Ouest and Caisse d’Epargne Hauts de
France, contributed to the financing of the acquisition.

Share the Post:

Related Posts